Phase 4
Completed N=44
Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)
Source: ClinicalTrials.gov NCT01595516 ↗Enrolled (actual)
44
Serious AEs
0.0%
Results posted
Jun 2019
Primary outcomePrimary: Heart Rate — 64; 71; 69; 58 bpm
◆ Published Evidence
Emerging
9citations · ~1 / year
Nebivolol, But Not Metoprolol, Treatment Improves Endothelial Fibrinolytic Capacity in Adults With Elevated Blood Pressure.
Summary
The investigators hypothesize that nebivolol will improve endothelial t-PA release in adult humans with elevated blood pressure to a greater extent than either metoprolol or placebo. The investigators further hypothesize that the improvement in the capacity of the vascular endothelium to release t-PA with nebivolol is mediated, in part, by the compound's antioxidant properties.
Linked Publications
-
Nebivolol, But Not Metoprolol, Treatment Improves Endothelial Fibrinolytic Capacity in Adults With Elevated Blood Pressure.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Heart Rate |
64; 71; 69; 58; 64; 72 | — |
| PRIMARY Systolic Blood Pressure |
140; 138; 138; 125; 125; 135 | — |
| PRIMARY Diastolic Blood Pressure |
85; 87; 85; 78; 79; 81 | — |
| PRIMARY Endothelial t-PA Release in Response to Bradykinin (BDK) Before and After the 12 Week Intervention |
-1.2; -1.8; -1.2; -1.9; -0.2; -0.9 | — |
| PRIMARY Endothelial t-PA Release in Response to Bradykinin (BDK) and Bradykinin+Vitamin C (BDK+C) Before and After 12 Weeks of Nebivolol Therapy. |
-2.4; -1.4; -1.5; -3.8; 14.3; 31.3 | — |
| PRIMARY Endothelial t-PA Release in Response to BDK and BDK+C Before and After 12 Weeks of Metoprolol Therapy. |
-2.7; -2.5; -1.3; -2.7; 10.1; 31.1 | — |
Eligibility Criteria
Inclusion Criteria
- Subjects will be men and women of all races and ethnic backgrounds aged 45-65 years.
- Subjects will be prehypertensive/hypertensive defined as resting systolic blood pressure >125 mmHg and 80 mmHg and 126 mg/dL.
- Potential candidates with a resting heart rate of 160 mmHg or a seated diastolic blood pressure >100 mmHg will be excluded.
Data sourced from ClinicalTrials.gov (NCT01595516) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.